Stockholm, Sweden, 2025-07-10 - Symcel, an analytical technology innovator specializing in rapid microbial detection and direct metabolic measurements, announces two significant appointments that further strengthen the company’s strategic and operational capacity.
Stefan Linder appointed to Symcel´s Board of Directors
Symcel welcomes Stefan Linder to its Board of Directors. Stefan brings a wealth of experience in company strategy, growth and transactions in the Nordic tech and investment ecosystem. For nearly two decades, he was a key partner at Altor Equity Partners, one of Sweden’s most successful private equity firms. With a strong track record in scaling technology-driven companies, Stefan brings critical strategic acumen to Symcel’s growth journey.
“Symcel is solving fundamental problems within advanced therapies and diagnostics in a novel way. I am impressed by the team, innovation pace and the technical solutions, and very happy to join this journey,” says Stefan Linder.
Dr. Robert Tönhardt joins as Director of Product Development
Symcel also announces the appointment of Dr. Robert Tönhardt as Director of Product Development, a newly created position reflecting the company’s commitment to scaling innovation and execution across its R&D platform.
Robert brings deep expertise in instrument and medtech product development and cross-functional team leadership, with a proven record of transforming scientific vision into market-ready solutions. In this executive leadership role, he is responsible for spearheading Symcel’s product development efforts across instruments, software, and consumables. His leadership will be instrumental in delivering on key development milestones in the coming years.
“Symcel is entering an exciting phase with strong momentum in the market and bold ambitions. I’m excited to join the team to lead product development and accelerate our impact in rapid sterility testing and research workflows,” says Robert Tönhardt.
A Strategic Platform for Growth
With these appointments, Symcel is further positioning itself to deliver on its vision of establishing its solutions as the new gold standard for rapid sterility testing of advanced therapies and eventually for bacterial diagnostics and antimicrobial resistance.
Commenting on the appointments, Dr. Jesper Ericsson, CEO of Symcel, stated:
“These strategic reinforcements – both at Board level and in our leadership team – reflect our commitment to building breakthrough technologies with a top organisation and delivering on the promise of rapid diagnostics and smart R&D tools. Stefan is an exceptionally experienced investor and advisor with a strong ability to connect operational and strategic execution. Robert brings broad and deep knowledge in all aspects of analytical instrument and medtech development. I am thrilled to work directly with both Stefan and Robert in our growth journey.” said Jesper Ericsson.
Media contact:
Per Lidén, Marketing Manager
per.liden@symcel.com